4//SEC Filing
Thompson Peter A. 4
Accession 0000950170-25-017031
CIK 0002036042other
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 4:05 PM ET
Size
12.7 KB
Accession
0000950170-25-017031
Insider Transaction Report
Form 4
Thompson Peter A
Director
Transactions
- Conversion
Series C convertible preferred stock
2025-02-10−2,048,760→ 0 total(indirect: By OrbiMed Private Investments VIII, LP)→ Common Stock (1,402,204 underlying) - Conversion
Series B convertible preferred stock
2025-02-10−2,560,951→ 0 total(indirect: By OrbiMed Private Investments VIII, LP)→ Common Stock (1,752,755 underlying) - Conversion
Common Stock
2025-02-10+3,154,959→ 3,154,959 total(indirect: By OrbiMed Private Investments VIII, LP) - Purchase
Common Stock
2025-02-10$18.00/sh+550,000$9,900,000→ 3,704,959 total(indirect: By OrbiMed Private Investments VIII, LP)
Footnotes (4)
- [F1]Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.
- [F2]The securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
- [F3]Each of OrbiMed Advisors, GP VIII and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F4]Reflects shares purchased in the Issuer's initial public offering.
Documents
Issuer
Sionna Therapeutics, Inc.
CIK 0002036042
Entity typeother
Related Parties
1- filerCIK 0001357522
Filing Metadata
- Form type
- 4
- Filed
- Feb 9, 7:00 PM ET
- Accepted
- Feb 10, 4:05 PM ET
- Size
- 12.7 KB